News

The expanded facility features a 90-bed sleeping area, exam and procedure rooms, pharmacy, in-patient and outpatient fully equipped laboratories and attractive and comfortable subject spaces with recreational areas,

Following the acquisition, Phadia will be part of Thermo Fisher’s Specialty Diagnostics business within its Analytical Technologies Segment. Thermo Fisher will leverage Phadia’s clinical marketing model to sell

ShangPharma has reported a net income of $3.01m, or $0.16 per diluted share, compared to net income of $2.73m or $0.18 per diluted share, for the same period

Under the agreement, both the companies will develop fluid systems and market single-use tubing, which will be produced by Raumedic and will supply to SSB. SSB will combine

APP Pharmaceuticals develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. Gemcitabine HCI for Injection is indicated

RG3039, an orally bioavailable compound, is an inhibitor of an RNA processing enzyme which targets SMN2. The trial is designed to investigate the safety and pharmacokinetic of escalating

The results of the trial suggested that olaparib 400mg twice daily extended progression free survival (PFS) by RECIST compared to placebo Median PFS: 8.4 vs 4.8 months respectively.

Synergy Outsourcing, part of UK based scientific recruiter SRG, is a functional service provider of on and off site outsourced services across the chemistry, quality and biochemistry industries.

MetMAb, a monovalent (one-armed), monoclonal antibody is designed to block Met signaling in cancer cells by binding specifically to the cell surface Met receptor, blocking HGF-mediated activation. MetMAb